300 related articles for article (PubMed ID: 28052356)
1. An Overview of the Changing Landscape of Treatment for Advanced Melanoma.
Lee CS; Thomas CM; Ng KE
Pharmacotherapy; 2017 Mar; 37(3):319-333. PubMed ID: 28052356
[TBL] [Abstract][Full Text] [Related]
2. The Emerging Therapeutic Landscape of Advanced Melanoma.
Henriques V; Martins T; Link W; Ferreira BI
Curr Pharm Des; 2018; 24(5):549-558. PubMed ID: 29366407
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in malignant melanoma.
Atkinson V
Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
[TBL] [Abstract][Full Text] [Related]
4. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
5. [Melanoma update].
Longvert C; Saiag P
Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma.
Franke V; van der Hiel B; van de Wiel BA; Klop WMC; Ter Meulen S; van Akkooi ACJ
Eur J Cancer; 2018 Feb; 90():149-152. PubMed ID: 29224902
[No Abstract] [Full Text] [Related]
7. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; RĂ©gis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
8. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
9. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Melanoma.
Glitza Oliva IC; Alqusairi R
Adv Exp Med Biol; 2018; 995():43-63. PubMed ID: 30539505
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy for malignant melanoma].
Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
[TBL] [Abstract][Full Text] [Related]
12. Major Changes in Systemic Therapy for Advanced Melanoma.
Thompson JA
J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):638-40. PubMed ID: 27226502
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous melanoma.
Eggermont AM; Spatz A; Robert C
Lancet; 2014 Mar; 383(9919):816-27. PubMed ID: 24054424
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
Levine O; Devji T; Xie F
Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
[No Abstract] [Full Text] [Related]
16. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
Lau PK; Ascierto PA; McArthur G
Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
[TBL] [Abstract][Full Text] [Related]
17. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ; Flaherty KT; Ribas A; Long GV
Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
[TBL] [Abstract][Full Text] [Related]
18. Melanoma: from darkness to promise.
Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
[TBL] [Abstract][Full Text] [Related]
19. Current trends in the treatment of malignant melanoma.
Valko-Rokytovska M; Bruchata K; Simkova J; Milkovicova M; Kostecka Z
Neoplasma; 2016; 63(3):333-41. PubMed ID: 26925781
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]